PRINCETON JUNCTION, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Alpha Capital Corp ("Alpha"), a global merchant bank, is pleased to announce that it has been retained as the exclusive financial advisor to CD8 Technology Services, LLC ("CD8 Technology") in connection with financing a real estate facility whose primary focus is developing and manufacturing biologic products for cell therapy. By eliminating barriers to entry, in terms of capital and time to build GMP capabilities at scale, this venture will expedi ...

CD8 Technology Services, LLC ("CD8 Technology") to provide turn-key facility for Tevogen Bio Reinforces Tevogen Bio's commitment to preserving shareholder value Expected to further enhance Tevogen Bio's ambitious growth agenda WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, took si ...

WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today provided additional guidance on the first clinical product of the company's proprietary ExacTcell™ technology, TVGN 489, designed to treat SARSCoV-2 infections in immunocompromised oncology patients, and a subgroup of patients w ...

WARREN, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to provide further updates on the previously announced revenue forecast for Tevogen Oncology and Tevogen Specialty Care therapeutic areas by the end of this week. The revenue forecast for the two therapeutic areas is approximate ...

WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, reported last week that Chief Scientific Officer (CSO) Dr. Neal Flomenberg sold shares. Tevogen's Chief Financial Officer, Kirti Desai, clarified that the sale was made solely to satisfy the payment of tax obligations relating to the ...

WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Since being founded in 2020, Tevogen Bio has taken a unique approach to both drug development and managing its business operations. The company launched is proprietary ExacTcell™ technology, designed to create accessible and disease ...

Total eligible patients in the US exceed 2 million. Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment. Reflects business philosophy of commercial success through patient accessibility. WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, t ...

WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- HMP Partners and The Patel Family LLP, leading investors in innovative healthcare ventures, congratulate Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN) and founding CEO Dr. Ryan Saadi for being honored with prestigious proclamation by the Township of Warren, New Jersey, in recognition of their Nobel Prize nomination for pioneering business model to alleviate health inequality through breakthrough life-saving medical innovations. Warren T ...

Approximately one in three women remain HPV positive after cervical procedures for precancerous lesions. Tens of thousands of women in the US each year are diagnosed with high-grade cervical precancerous lesions. These high-grade cervical lesions can reoccur, requiring more treatment, and potentially lead to cervical cancer. Nearly all cervical cancer and high-grade cervical lesions are associated with HPV which promotes cancer formation. The primary risk factor for the recurrence of high-grade cervical les ...

WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to share its $1B+ revenue potential, a reflection of the company's novel business approach. "In the current market reality, Tevogen Bio's unique, faster, and cost-efficient drug development model has the potential to serve as a ...